Linked Life Data

3005396

Source:http://linkedlifedata.com/resource/pubmed/id/3005396

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3005396rdf:typepubmed:Citationlld:pubmed
pubmed-article:3005396lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3005396lifeskim:mentionsumls-concept:C0229664lld:lifeskim
pubmed-article:3005396lifeskim:mentionsumls-concept:C0024264lld:lifeskim
pubmed-article:3005396pubmed:issue5lld:pubmed
pubmed-article:3005396pubmed:dateCreated1986-4-1lld:pubmed
pubmed-article:3005396pubmed:abstractTextTo investigate the ability of interleukin 2 (IL 2) alone to induce proliferation of resting human lymphocytes, we stimulated human peripheral blood mononuclear cells (PBMC) with an immunopurified preparation of IL 2 or with phytohemagglutinin (PHA). Proliferation and the percent of cells expressing IL 2 receptors were assessed over 6 days of culture. Regardless of the stimulus, the percent of cells bearing an IL 2 receptor paralleled the amount of proliferation, and proliferation was inhibited by an anti-IL 2 receptor monoclonal antibody (anti-Tac). When stimulated by IL 2 alone, less than 8% of PBMC expressed an IL 2 receptor after 24 hr of culture. Stimulation by IL 2 caused both proliferation and IL 2 receptor expression to increase over the entire culture period (routinely to 75,000 cpm and 50% respectively). When colchicine was added (to inhibit cell division), the percent of cells bearing an IL 2 receptor did not increase. IL 2 alone also induced proliferation of PBMC depleted of accessory cells, with the same kinetics but reduced peak response. Both accessory cells and supernatants that showed IL 1 but not IL 2 activity augmented this proliferation 50 to 100%. In contrast to the effect of IL 2, 25 to 50% of PBMC stimulated by PHA expressed an IL 2 receptor after 24 hr of culture. PHA-induced proliferation and IL 2 receptor expression peaked early in the culture period (routinely to 100,000 cpm and 50% respectively within 3 days), and colchicine did not inhibit the early induction of IL 2 receptors on PBMC. Our findings indicate that unlike PHA, IL 2 induces proliferation of PBMC (or PBMC depleted of accessory cells) by expanding the small percentage of cells in a resting population that already express IL 2 receptors. IL 2 does not appear to induce IL 2 receptors on cells previously lacking this molecule. We also find that IL 1 can enhance the response to IL 2 alone.lld:pubmed
pubmed-article:3005396pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:languageenglld:pubmed
pubmed-article:3005396pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3005396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3005396pubmed:statusMEDLINElld:pubmed
pubmed-article:3005396pubmed:monthMarlld:pubmed
pubmed-article:3005396pubmed:issn0022-1767lld:pubmed
pubmed-article:3005396pubmed:authorpubmed-author:NowellP CPClld:pubmed
pubmed-article:3005396pubmed:authorpubmed-author:TaylorD SDSlld:pubmed
pubmed-article:3005396pubmed:authorpubmed-author:KernJ AJAlld:pubmed
pubmed-article:3005396pubmed:issnTypePrintlld:pubmed
pubmed-article:3005396pubmed:day1lld:pubmed
pubmed-article:3005396pubmed:volume136lld:pubmed
pubmed-article:3005396pubmed:ownerNLMlld:pubmed
pubmed-article:3005396pubmed:authorsCompleteYlld:pubmed
pubmed-article:3005396pubmed:pagination1620-4lld:pubmed
pubmed-article:3005396pubmed:dateRevised2007-11-14lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:meshHeadingpubmed-meshheading:3005396-...lld:pubmed
pubmed-article:3005396pubmed:year1986lld:pubmed
pubmed-article:3005396pubmed:articleTitleIL 2 alone is mitogenic only for Tac-positive lymphocytes in human peripheral blood.lld:pubmed
pubmed-article:3005396pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3005396pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:3005396pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3005396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3005396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3005396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3005396lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3005396lld:pubmed